Skip to main content

Advertisement

Table 6 Multivariate analysis of factors for the ratio of CD8+ TIL to Foxp3+ TIL and Foxp3+ TIL combined with Granzyme B+ TIL with survival

From: Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways

Variables OS (n = 106) PFS (n = 106)
  Hazard Ratio 95% CI P Hazard Ratio 95% CI P
The ratio of CD8 to Foxp3       
Tumor (T) stage (4+3/2+1) 1.007 0.419-2.420 0.988 1.185 0.523-2.686 0.685
Nodal (N) status (3+2+1/0) 4.172 0.545-31.939 0.169 2.821 0.655-12.154 0.164
TNM stage (III+IVa+IVb/I+II) 2.444 0.754-7.928 0.136 1.561 0.569-4.286 0.387
CD8/Foxp3 (high/low) 1.898 0.885-4.071 0.100 2.393 1.174-4.874 0.016*
Combination of Foxp3 and GrB       
Tumor (T) stage (4+3/2+1) 0.647 0.256-1.639 0.359 0.750 0.318-1.768 0.510
Nodal (N) status (3+2+1/0) 5.798 0.757-44.421 0.091 4. 681 1.080-20.280 0.039*
TNM stage (III+IVa+IVb/I+II) 3.078 0.940-10.075 0.063 2.093 0.759-5.78 0.153
Combination of Foxp3 + and Granzyme B + TIL       
Overall NA   0.028* NA   0.001*
Foxp3GrB high VS Foxp3GrB low 0.314 0.111-0.887 0.029* 0.197 0.072-0.540 0.002*
  1. Note: *significant. Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression-free survival; NA, not applicable.